Clinically, the PAM molecule evocalcet, used in the treatment of secondary hyperparathyroidism, is bound to the 7TM domain of the CaSR by hydrophobic interactions with residues Phe683, Phe687, Trp817, and Ile840. This evidence concerns the gene CASR and secondary hyperparathyroidism.